|
|
|
MIRA INFORM REPORT
|
Report No. : |
486235 |
|
Report Date : |
20.01.2018 |
IDENTIFICATION DETAILS
|
Name : |
SYNBIAS PHARMA AG |
|
|
|
|
Registered Office : |
Pestalozzistrasse 2 CH-8200 Schaffhausen |
|
|
|
|
Country : |
Switzerland |
|
|
|
|
Date of Incorporation : |
07.02.2012 |
|
|
|
|
Com. Reg. No.: |
290.3.017.421-0 |
|
|
|
|
Legal Form : |
Company Limited By Shares |
|
|
|
|
Line of Business : |
Subject is an contract manufacturing
partner for pharmaceutical companies worldwide. The company manufacture
Active Pharmaceutical Ingredients and Final Dosage Forms and provide
comprehensive support during registration. The company is a specialist in
manufacturing of high quality oncology pharmaceutical drugs. |
|
|
|
|
No. of Employees : |
50-79 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
B |
|
Credit Rating |
Explanation |
Rating Comments |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.06.2017) |
Current Rating (30.09.2017) |
|
Switzerland |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
SWITZERLAND - ECONOMIC
OVERVIEW
Switzerland, a country that espouses neutrality, is a prosperous and modern market economy with low unemployment, a highly skilled labor force, and a per capita GDP among the highest in the world. Switzerland's economy benefits from a highly developed service sector, led by financial services, and a manufacturing industry that specializes in high-technology, knowledge-based production. Its economic and political stability, transparent legal system, exceptional infrastructure, efficient capital markets, and low corporate tax rates also make Switzerland one of the world's most competitive economies.
The Swiss have brought their economic practices largely into conformity with the EU's to enhance their international competitiveness, but some trade protectionism remains, particularly for its small agricultural sector. The fate of the Swiss economy is tightly linked to that of its neighbors in the euro zone, which purchases half of Swiss exports. The global financial crisis of 2008 and resulting economic downturn in 2009 stalled demand for Swiss exports and put Switzerland into a recession. During this period, the Swiss National Bank (SNB) implemented a zero-interest rate policy to boost the economy, as well as to prevent appreciation of the franc, and Switzerland's economy began to recover in 2010.
The sovereign debt crises unfolding in neighboring euro-zone countries, however, coupled with ongoing economic instability in Russia and other eastern European economies continue to pose a significant risk to the Swiss economy, driving up demand for the Swiss franc by investors seeking a safe-haven currency. In January 2015, the SNB abandoned the Swiss franc’s peg to the euro, roiling global currency markets and making active SNB intervention a necessary hallmark of present-day Swiss monetary policy. The independent SNB has upheld its zero interest rate policy and conducted major market interventions to prevent further appreciation of the Swiss franc, but parliamentarians have urged it to do more to weaken the currency. The franc's strength has made Swiss exports less competitive and weakened the country's growth outlook; GDP growth fell below 2% per year from 2011-17.
In recent years, Switzerland has responded to increasing pressure from neighboring countries and trading partners to reform its banking secrecy laws, by agreeing to conform to OECD regulations on administrative assistance in tax matters, including tax evasion. The Swiss government has also renegotiated its double taxation agreements with numerous countries, including the US, to incorporate OECD standards, and is openly considering the possibility of imposing taxes on bank deposits held by foreigners.
|
Source
: CIA |
company
name
Synbias Pharma AG
Operating address
Pestalozzistrasse 2
8200 Schaffhausen/SH
Switzerland/CH
Telephone: +41
526204536
Fax: +41
526204538
Web site: http://www.synbiaspharma.com
E-mail: info@synbiaspharma.ch
WIN Worldbox No.: CH0009313834
VAT-No.: CHE-320.462.859 MWST
UID-No.: CHE320462859
Profile
Established: 2012
Line of Business: Consumer goods wholesale
Industry Division: Wholesale trade
Industry-code (NACE): 4646 Wholesale of pharmaceutical goods
Banks: unknown
Operational Figures
Coverage: Company
Figures: estimated
Financial year: 2017
Employees: 50-79
Sales: CHF 10-20 Mio
Activity
The company is an contract
manufacturing partner for pharmaceutical companies worldwide. The company
manufacture Active Pharmaceutical Ingredients and Final Dosage Forms and
provide comprehensive support during registration. The company is a specialist
in manufacturing of high quality oncology pharmaceutical drugs.
Products:
Anthracyclines:
- Doxorubicin Hydrochloride
- Epirubicin Hydrochloride
- Idarubicin Hydrochloride
- Valrubicin
- Pirarubicin
Plant Alkaloid Derivates:
- Vinorelbine Bitartate
- Irinotecan Hydrochloride
- Topotecan Hydrochloride
Nucleosides:
- Cladribine
- Nelarabine
- Clofarabine
- Fludarabine
- Decitabine
Others:
- Mitoxantrone
Hydrochloride
- Pipecuronium Bromide
Operations and Branches:
At the address,
Pestalozzistrasse 2, 8200 Schaffhausen, Switzerland, we find office of the
company.
Real Estate
Real Estate: The company does not appear
to own any property.
Company Register
Company No: 290.3.017.421-0
UID-No.: CHE320462859
Legal form: Company limited by shares
Registration: 07.02.2012
Legal status: active
Responsible
Register: Handelsregister des Kantons
Schaffhausen
History: Date of Incorporation
Statutes: 07.02.2012
Entry Deleted Name
07.02.2012 Synbias
Pharma AG
07.02.2012 Synbias
Pharma SA (Name translated)
07.02.2012 Synbias
Pharma Ltd (Name translated)
Entry Deleted Legal domicile
07.02.2012 Schaffhausen,
Switzerland
Entry Deleted Address
29.02.2012 Pestalozzistrasse
2, 8200 Schaffhausen/SH, Switzerland/CH
07.02.2012 29.02.2012 Bachstrasse 56, 8200 Schaffhausen/SH,
Switzerland/CH
Entry Deleted Capital
07.02.2012 Share
Capital CHF 100,000, paid up CHF 100,000
Entry Deleted Capital Structure
07.02.2012 100
Registered shares of EUR 1,000.--
Official Administration
Title Name
President Lugovoi,
Ivan
Citizen:
Ukraine
Residential
address: Paris, France
single
signature
Registered
since: 23.05.2016
Director Alder,
Hans Rudi
Citizen:
Schwellbrunn, Switzerland
Residential
address: Schaffhausen, Switzerland
single
signature
Registered
since: 25.02.2015
External Positions
Title Name
Auditor Lienhard
Audit AG,
Residential
address: Zürich, Switzerland
Id:
CHE-139.583.547
Registered
since: 17.05.2016
Direct owner/-s
No. of owner/-s: 2
Owner: The company is
domestic owned.
Class: 50-100%, directly
held
Name: SPG Invest GmbH
City/Country: Schaffhausen/SH,
Switzerland/CH
Interest: 85,00% voting right,
85,00% capital interest
Class: 10-19%, directly
held
Name: ST Investment GmbH
City/Country: Schaffhausen/SH,
Switzerland/CH
Interest: 15,00% voting right,
15,00% capital interest
Investments
It is believed that the
company has no investments.
Financials
Balance sheet publication:
The subject company does not
publish financial figures.
Legal Actions
No legal actions
determined.
An updated legal action
check is only available against proof of interest. e.g. a copy of an enquiry
letter, and order or invoice relating to the subject company.
Sanctions List
We did not find the company
included on the various international sanctions lists, such as the OFAC (Office
of Foreign Assets Control), the BIS (Bureau of Industry and Security), the
European Union Restrictive measures (sanctions) list, the Export Control
Organisation (ECO) of the UK, the Australian Department of Foreign Affairs and
Trade.
Payment experiences
Payment experiences are
considered to be in order.
Credit Information
Financial Statements: The company does not disclose any financial statements. Third
parties are not permitted any insight into the financial affairs. It is
therefore difficult to make a proper assessment of the actual situation.
Financial Situation: The financial situation is difficult to assess.
Payment experiences: There are no objections regarding the payment of financial
obligations.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 63.72 |
|
|
1 |
INR 88.64 |
|
Euro |
1 |
INR 78.14 |
|
SWISS |
1 |
INR 66.30 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
VAR |
|
|
|
|
Report Prepared
by : |
POJ |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.